Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
NCT00440609
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
50
Enrollment
OTHER
Sponsor class
Conditions
Clinically Significant Diabetic Macular Edema
Interventions
DRUG:
ranibizumab
Sponsor
Philip J. ferrone, M.D.